GlassScriptPhysician profile
Chinwe Obinwa
NPI 1053701102
$1,664.89
in general payments reported to CMS, 2019-2025
25 companies · $917 in 2025
The $917 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $207 · 2022: $336 · 2023: $52.95 · 2024: $152 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,122.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $216.50 | 2024-2025 | Gemtesa, Orgovyx |
| Boston Scientific Corporation | $206.83 | 2025 | Ams 700, Rezum Generator, Spaceoar Vue System - 10ml |
| Endo USA, INC. | $176.87 | 2024-2025 | Xiaflex, Aveed |
| Mallinckrodt Hospital Products INC. | $137.34 | 2022 | |
| Ferring Pharmaceuticals INC. | $105.15 | 2024-2025 | Adstiladrin |
| Urogen Pharma, INC. | $89.04 | 2021-2025 | |
| Tolmar, INC. | $87.01 | 2025 | Eligard, Jatenzo |
| Pfizer INC. | $84.99 | 2021 | |
| Abc Home Medical Supply, INC. | $69.52 | 2025 | |
| Aurinia Pharma U.S., INC. | $61.36 | 2022 | |
| 180 Medical, INC. | $46.40 | 2025 | Speedicath, Gentlecath |
| Vifor Pharma, INC. | $44.19 | 2022-2023 | Veltassa |
| Convatec INC. | $43.80 | 2021 | |
| Teleflex LLC | $38.29 | 2024 | Urolift |
| Janssen Biotech, INC. | $34.37 | 2025 | Erleada |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $29.58 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.19 | 2022 | |
| Valencia Technologies Corporation | $26.01 | 2025 | Ecoin Device Kit |
| Calliditas Therapeutics US INC. | $24.54 | 2023 | Tarpeyo |
| Fresenius USA Marketing, INC. | $23.37 | 2022 | |
| Glaxosmithkline, LLC. | $21.91 | 2022 | |
| Merck Sharp & Dohme LLC | $21.02 | 2025 | Keytruda |
| Allergan, INC. | $18.45 | 2021 | |
| Photocure INC | $16.07 | 2025 | Cysview |
| Myovant Sciences INC. | $13.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chinwe Obinwa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.